

# Gudrun Fleischhack

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/341672/publications.pdf>

Version: 2024-02-01

37  
papers

5,208  
citations

304743

22  
h-index

345221

36  
g-index

37  
all docs

37  
docs citations

37  
times ranked

8505  
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	27.8	1,872
2	The landscape of genomic alterations across childhood cancers. <i>Nature</i> , 2018, 555, 321-327.	27.8	1,068
3	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. <i>Lancet Oncology</i> , The, 2018, 19, 785-798.	10.7	268
4	Divergent clonal selection dominates medulloblastoma at recurrence. <i>Nature</i> , 2016, 529, 351-357.	27.8	266
5	Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. <i>European Journal of Cancer</i> , 2016, 65, 91-101.	2.8	262
6	Childhood cancer predisposition syndromes – A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 1017-1037.	1.2	200
7	Treatment of young children with localized medulloblastoma by chemotherapy alone: Results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. <i>Neuro-Oncology</i> , 2011, 13, 669-679.	1.2	149
8	BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. <i>Oncotarget</i> , 2013, 4, 2080-2095.	1.8	122
9	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. <i>Cancer Discovery</i> , 2021, 11, 2764-2779.	9.4	110
10	Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. <i>Journal of Neuro-Oncology</i> , 2016, 129, 515-524.	2.9	99
11	Pharmacokinetics Following Intraventricular Administration of Chemotherapy in Patients with Neoplastic Meningitis. <i>Clinical Pharmacokinetics</i> , 2005, 44, 1-31.	3.5	94
12	Evidence of H3 K27M mutations in posterior fossa ependymomas. <i>Acta Neuropathologica</i> , 2016, 132, 635-637.	7.7	73
13	High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): a report from the European Rhabdoid Registry (EU-RHAB). <i>Bone Marrow Transplantation</i> , 2014, 49, 370-375.	2.4	58
14	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. <i>Journal of Clinical Oncology</i> , 2020, 38, 2028-2040.	1.6	58
15	Nimotuzumab treatment of malignant gliomas. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1649-1659.	3.1	53
16	Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. <i>Journal of Antimicrobial Chemotherapy</i> , 2001, 47, 841-853.	3.0	49
17	Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. <i>British Journal of Cancer</i> , 2001, 84, 1453-1459.	6.4	48
18	Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy. <i>European Journal of Cancer</i> , 2015, 51, 2634-2642.	2.8	44

#	ARTICLE	IF	CITATIONS
19	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	1.6	40
20	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion-Positive Supratentorial Ependymomas. <i>Cancer Discovery</i> , 2021, 11, 2230-2247.	9.4	39
21	Strategies to improve the quality of survival for childhood brain tumour survivors. <i>European Journal of Paediatric Neurology</i> , 2015, 19, 619-639.	1.6	36
22	Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study. <i>Journal of Neuro-Oncology</i> , 2019, 143, 107-113.	2.9	25
23	Treatment of recurrent primitive neuroectodermal tumors (PNET) in children and adolescents with high-dose chemotherapy (HDC) and stem cell support: results of the HITREZ 97 multicentre trial. <i>Journal of Neuro-Oncology</i> , 2014, 120, 635-642.	2.9	21
24	Postponed Is Not Canceled: Role of Craniospinal Radiation Therapy in the Management of Recurrent Infant Medulloblastoma—An Experience From the HIT-REZ 1997 & 2005 Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1019-1024.	0.8	21
25	Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study. <i>Neuro-Oncology</i> , 2021, 23, 1012-1023.	1.2	19
26	Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors. <i>Journal of Neuro-Oncology</i> , 2016, 128, 463-471.	2.9	18
27	Functional loss of a noncanonical BCOR-PRC1.1 complex accelerates SHH-driven medulloblastoma formation. <i>Genes and Development</i> , 2020, 34, 1161-1176.	5.9	16
28	Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment. <i>PLoS ONE</i> , 2020, 15, e0227693.	2.5	14
29	Cyanotic Raynaud's phenomenon with conventional but not with liposomal amphotericin B: three case reports. <i>Mycoses</i> , 1997, 40, 359-361.	4.0	13
30	Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia. <i>Leukemia</i> , 2021, 35, 2650-2657.	7.2	13
31	Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment. <i>Cancers</i> , 2022, 14, 126.	3.7	12
32	Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study. <i>Cancers</i> , 2022, 14, 471.	3.7	9
33	Eye Tumors in Childhood as First Sign of Tumor Predisposition Syndromes: Insights from an Observational Study Conducted in Germany and Austria. <i>Cancers</i> , 2021, 13, 1876.	3.7	7
34	Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies. <i>Journal of Neuro-Oncology</i> , 2021, 155, 193-202.	2.9	6
35	The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma. <i>Cancers</i> , 2022, 14, 679.	3.7	4
36	Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. <i>British Journal of Haematology</i> , 2000, 111, 1093-1102.	2.5	2

#	ARTICLE	IF	CITATIONS
37	Treatment of relapsed AML in children. British Journal of Haematology, 1999, 104, 420-421.	2.5	0